Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H31NO6 |
Molecular Weight | 429.506 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1
InChI
InChIKey=FFYNAVGJSYHHFO-UHFFFAOYSA-N
InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)
Molecular Formula | C24H31NO6 |
Molecular Weight | 429.506 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17438407Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/sarpogrelate.html | https://www.ncbi.nlm.nih.gov/pubmed/10980267 | https://clinicaltrials.gov/ct2/show/NCT01165567 | http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17438407
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/sarpogrelate.html | https://www.ncbi.nlm.nih.gov/pubmed/10980267 | https://clinicaltrials.gov/ct2/show/NCT01165567 | http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF
Sarpogrelate (brand name Anplag; former developmental code names MCI-9042, LS-187,118) is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. It blocks serotonin-induced platelet aggregation and has applications in the treatment of many diseases including diabetes mellitus, Buerger's disease, Raynaud's disease, coronary artery disease, angina pectoris, and atherosclerosis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10980267
Curator's Comment: According to information supplied by the manufacturers, the brain tissue concentration of sarpogrelate was 0.25–0.5% of the plasma concentration, in a w14 tracer experiment using Cx-labeled sarpogrelate
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8937629 |
8.38 nM [Ki] | ||
Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17609583 |
6.11 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Anplag Approved UseINDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion |
|||
Preventing | Anplag Approved UseINDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.3636 μg/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.7218 μg/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
565 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
506.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
62.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
49.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
721.4 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
467.3 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
761 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.2908 μg × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.5958 μg × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1754 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1358.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
361 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
291.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2352.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1927.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1772.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.753 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.753 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
0.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SARPOGRELATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5% |
SARPOGRELATE serum | Homo sapiens |
||
96.8% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24167220/ |
SARPOGRELATE plasma | Homo sapiens |
||
72% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24167220/ |
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma | Homo sapiens |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Elevated liver enzymes, Upper gastrointestinal symptoms... Other AEs: Elevated liver enzymes (3.3%) Sources: Upper gastrointestinal symptoms (0.8%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Upper gastrointestinal symptoms | 0.8% | 200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Elevated liver enzymes | 3.3% | 200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [Inhibition 10 uM] | ||||
no [Inhibition 10 uM] | ||||
no [Inhibition 10 uM] | ||||
no [Inhibition 10 uM] | ||||
Page: 54.0 |
no | |||
yes [IC50 0.195 uM] | yes (co-administration study) Comment: Co-administration increased Metoprolol AUCt by 1.53-fold and Cmax by 1.62-fold Page: 1.0 |
|||
yes [IC50 0.201 uM] | ||||
Page: 6.0 |
yes [IC50 19.4971 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
minor [Km 96.3 uM] | ||||
Page: 34.0 |
no | |||
yes [Km 186.6 uM] | ||||
yes [Km 476.2 uM] | ||||
yes [Km 564.1 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Serotonin potentiates angiotensin II--induced vascular smooth muscle cell proliferation. | 2001 Dec |
|
Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. | 2001 Dec 21 |
|
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. | 2001 Jul |
|
Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. | 2001 Jul-Aug |
|
Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. | 2001 Jun |
|
Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists. | 2001 Nov |
|
Binding affinity of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane. | 2001 Oct |
|
Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart. | 2001 Sep |
|
[Involvement of peripheral 5-HT2A receptor activation in inflammatory pain]. | 2001 Sep |
|
AT-1015, a newly synthesized 5-HT2 receptor antagonist, dissociates slowly from the 5-HT2 receptor sites in rabbit cerebral cortex membrane. | 2002 Aug |
|
Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris. | 2002 Aug |
|
Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril. | 2002 Feb |
|
Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. | 2002 Feb 1 |
|
DOI, a 5-HT2 receptor agonist, induces renal vasodilation via nitric oxide in anesthetized dogs. | 2002 Feb 15 |
|
Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. | 2002 Jan |
|
[Pharmacological analysis of inhibitory effect of sarpogrelate hydrochloride on human radial artery contraction]. | 2002 Jan |
|
Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease. | 2002 Jan |
|
Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: possible role of 5-hydroxytryptamine for diabetic bladder dysfunction. | 2002 Jul |
|
Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes. | 2002 May |
|
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. | 2003 Dec 1 |
|
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. | 2003 May |
|
The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. | 2003 May |
|
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. | 2003 May 30 |
|
Effects of R-102444, an orally active 5-HT2A receptor antagonist, in rat models of peripheral vascular disease. | 2004 Feb |
|
Sarpogrelate: cardiovascular and renal clinical potential. | 2004 Jul |
|
New treatment of lumbar disc herniation involving 5-hydroxytryptamine2A receptor inhibitor: a randomized controlled trial. | 2005 Apr |
|
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes. | 2005 Sep |
|
Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study. | 2006 May |
|
Livedo racemosa as a cutaneous manifestation of polycythemia vera. | 2006 May-Jun |
|
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. | 2006 Nov |
|
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury. | 2006 Sep 27 |
|
Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, attenuates neurogenic pain induced by nucleus pulposus in rats. | 2007 Feb 1 |
|
Identification of a key amino acid of the human 5-HT(2B) serotonin receptor important for sarpogrelate binding. | 2007 Jul |
|
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy. | 2008 Apr |
|
Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery. | 2008 Jul |
|
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. | 2008 Mar |
|
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. | 2009 Aug |
|
Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts. | 2009 Sep |
|
Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia. | 2010 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF
The usual dosage for adult patients is 100 mg of sarpogrelate hydrochloride, administered after meal three times a day. The dosage may be adjusted according to the patient’s age and symptoms.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17609583
Stably expressing cell lines were constructed in HEK293 cells by transfecting with Lipofectamine 2000 reagent and selecting with 0.5 mg/ml G418-containing growth medium. Cells were split into 24-well plates at a density of 105 cells /well and labeled with 3 μCi/ml [3H]myo-inositol in serum-free DMEM for 24 h. Then the cells were washed with the assay medium (20 mM LiCl, 130 mM NaCl, 900 μM NaH2PO4, 5.4 mM KCl, 1.8 mM CaCl2, and 25 mM glucose in 20 mM HEPES, pH 7.4) and incubated with both SARPOGRELATE (10−9 – 10−4 M) at 37°C for 1 h. Cell extracts, in 10 mM formic acid, were applied to a 1-ml AG1-X8 resin (100 – 200 mesh; Assist Co., Tokyo) column before elution by buffer containing 1 M ammonium formate and 0.1 M formic acid. Radioactivity was measured by a liquid scintillation spectrophotometer.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:16:38 GMT 2025
by
admin
on
Mon Mar 31 18:16:38 GMT 2025
|
Record UNII |
19P708E787
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7048328
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
6611
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
135309-80-7
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
SUPERSEDED | |||
|
5160
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
SUB10455MIG
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
19P708E787
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
2423
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
C064294
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
DB12163
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
C73158
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
CHEMBL52939
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
100000084098
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
210
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
125926-17-2
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY | |||
|
SARPOGRELATE
Created by
admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
COMPETITIVE INHIBITOR
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE ACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |